Animal Model Market Size & Growth Forecast 2026–2035, By Segments (End-use, Application Scope, Animal Type Scope), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Animal Model Market size was estimated at USD 2.64 Billion in 2025 and is projected to grow at a 8.8% CAGR from 2026 to 2035, exceeding USD 6.14 Billion by 2035. The industry revenue for 2026 is calculated at USD 2.84 billion.

• Base Year Value (2025): USD 2.64 Billion
• CAGR (2026-2035): 8.8%
• Forecast Year Value (2035): USD 6.14 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Animal Model Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds a 51.08% share due to its mature biomedical research ecosystem, strong funding, and extensive use of animal models in drug discovery and preclinical testing.
  • Asia Pacific is growing at a 9.94% CAGR driven by expanding life sciences research capacity, rising pharmaceutical activity, and increasing adoption of standardized preclinical testing systems.

• Segment Momentum:

  • Pharmaceutical & Biotechnology Companies held a 41.34% share in 2025 because they require animal models across drug discovery, preclinical validation, and pipeline development while maintaining in-house control over research execution and data continuity.
  • Contract Research Organizations are growing fastest as sponsors seek cost-efficient, flexible preclinical research support, helping reduce timelines and access specialized study capabilities without expanding internal infrastructure.

• Market Expansion Drivers:

  • Rising biopharmaceutical R&D activity increasing reliance on animal models for preclinical drug validation.
  • Growth of oncology and genetic research expanding use of mice-based experimental models.
  • Expansion of CRISPR and advanced gene-editing technologies enhancing translational research models.

• Leading Market Participants:

  Leading players in the animal model market include Charles River Laboratories International, Inc. (United States), The Jackson Laboratory (United States), Taconic Biosciences, Inc. (United States), genOway S.A. (France), Janvier Labs (France), Crown Bioscience Inc. (United States), Inotiv, Inc. (United States), Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (China), Envigo RMS LLC (United States), Harbour BioMed Ltd. (China).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 2.64 Billion
  • Projected Market Size: USD 6.14 Billion by 2035
  • Growth Forecasts: 8.8% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Pharmaceutical & Biotechnology Companies (End-use) | Cancer (Application Scope) | Mice (Animal Type Scope)
  • Emerging Opportunity Segment: Contract Research Organization (End-use) | Cancer (Application Scope) | Mice (Animal Type Scope)

Market Growth Drivers and Industry Trends

Rising biopharmaceutical R&D activity increasing reliance on animal models for preclinical drug validation

As biopharmaceutical pipelines become more crowded and biologics, cell therapies, and targeted therapeutics move deeper into development, preclinical programs are placing greater weight on in vivo evidence before compounds advance to human trials. That dynamic is driving demand for the animal model market because developers need pharmacokinetic, toxicity, efficacy, and mechanism-of-action data generated in systems that can better approximate whole-organism responses than in vitro methods alone. In practice, rising R&D activity increases study volumes, accelerates procurement of standardized research models, and supports market expansion for specialized breeding, disease-specific strains, and contract research services tied to preclinical validation workflows.

Growth of oncology and genetic research expanding use of mice-based experimental models

A large share of oncology and genetic research depends on mice because they offer well-characterized genomes, rapid breeding cycles, and strong compatibility with tumor biology and inherited disease studies, making them central to experimental design decisions. This is driving market development in the animal model market as academic centers, biotech firms, and pharmaceutical companies expand use of transgenic, knockout, xenograft, and patient-derived mouse models to investigate disease pathways and treatment response. The practical effect is increasing market penetration of highly specific mice-based platforms, with purchasing and model selection increasingly shaped by the need for reproducible phenotypes and faster alignment between early discovery findings and downstream therapeutic development.

Expansion of CRISPR and advanced gene-editing technologies enhancing translational research models

Wider use of CRISPR and related gene-editing tools is reshaping model creation by making it faster and more precise to generate animals that replicate human mutations, pathway disruptions, and disease progression patterns. That shift is contributing to market size growth in the animal model market because research teams are moving beyond generic strains toward customized translational models that better support target validation and biomarker research. In practice, gene-editing capabilities are influencing market adoption through higher demand for engineered lines, model development services, and breeding programs designed around specific genomic alterations, particularly where translational relevance directly affects go/no-go decisions in therapeutic research.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising biopharmaceutical R&D activity increasing reliance on animal models for preclinical drug validation	2.40%	High	North America, Europe	High	Near Term
Growth of oncology and genetic research expanding use of mice-based experimental models	2.10%	High	North America, Asia Pacific	High	Near Term
Expansion of CRISPR and advanced gene-editing technologies enhancing translational research models	1.70%	High	North America, Europe, Asia Pacific	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading animal model market position in 2025, accounting for a 51.08% share. This leadership is sustained by the region’s mature biomedical research ecosystem, where pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutes use animal models extensively in preclinical testing and disease research. Strong funding availability, established laboratory infrastructure, and consistent research activity support high purchasing volumes and repeat demand, while the concentration of experienced research institutions keeps model development and application closely tied to ongoing drug discovery and translational research workflows.

Asia Pacific is projected to expand at a 9.94% CAGR over the forecast period in the animal model market, backed by the rapid buildout of life sciences research capacity across the region. Growth is accelerating as pharmaceutical and biotechnology activity increases, research institutions broaden preclinical capabilities, and more studies move into organized laboratory settings that require standardized animal models. The region’s rising research investment is translating into greater model adoption in practice, particularly as local organizations expand disease-focused studies, toxicology work, and early-stage therapeutic development.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants/Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Translational Research Capacity

The U.S. animal model market is supported by extensive biomedical research, pharmaceutical development, and preclinical testing activities. Organizations in the U.S. continue investing in advanced disease models, genetically engineered strains, and specialized research services that improve translational study outcomes.

Japan

Advanced Disease Modeling

Japan continues advancing the animal model market through sophisticated disease research and precision biomedical studies. Research organizations in Japan emphasize genetically modified models and standardized laboratory practices that strengthen pharmaceutical and life science development programs.

South Korea

Biotechnology Research Support

South Korea is expanding the application of animal models across biotechnology, pharmaceutical development, and academic research. Institutions in South Korea invest in specialized research capabilities and modern laboratory infrastructure to support increasingly complex preclinical evaluation requirements.

Germany

Precision Research Models

Germany prioritizes high-quality animal models that support biomedical innovation, drug discovery, and translational research. Research institutions and commercial providers in Germany continue refining specialized models while emphasizing reproducibility, ethical practices, and regulatory compliance.

France

Preclinical Innovation Platform

France supports its animal model market through collaborative biomedical research and pharmaceutical innovation initiatives. Research facilities in France continue improving specialized model availability and laboratory capabilities to facilitate efficient preclinical studies across diverse therapeutic areas.

Italy

Academic Research Collaboration

Italy strengthens the animal model market through collaboration between research institutes, universities, and life science organizations. Scientific teams in Italy continue adopting specialized disease models and standardized research protocols that enhance the quality and consistency of preclinical investigations.

Segment Leadership and Growth Trends

  End-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs Contract Research Organization (Fastest-Growing Segment)

Pharmaceutical & Biotechnology Companies held the dominant position in the animal model market in 2025, accounting for a 41.34% share. This leadership is backed by their sustained need for animal models across drug discovery, preclinical validation, and pipeline progression, where in-house control over study design, timing, and data continuity remains critical. Large and mid-sized developers typically run broad research portfolios at the same time, which keeps demand concentrated within this end-use group and reinforces its share in the animal model market.

Contract Research Organization is the fastest-growing end-use segment in the animal model market as sponsors increasingly look for external partners that can execute preclinical work with greater flexibility and operational efficiency. Growth is being encouraged by the practical need to manage costs, shorten research timelines, and access specialized animal study capabilities without expanding internal infrastructure. Compared with fully in-house models, CRO engagement fits the rising preference for outsourced research workflows, which is strengthening momentum for this segment.

Application Scope Segment Analysis: Cancer (Largest & Fastest-Growing Segment)

In 2025, Cancer represented a 49.56% share of the animal model market, making it both the largest and fastest-growing application scope segment. Its strong position reflects the continued concentration of research activity around oncology, where animal models remain central to studying tumor biology, testing therapeutic response, and supporting preclinical development decisions. The same depth of ongoing oncology research is also sustaining faster growth in the animal model market, as developers continue to prioritize cancer-related programs that require reliable in vivo evidence before advancing to later development stages.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Pharmaceutical & Biotechnology Companies, Academic Research Institute, Contract Research Organization	Pharmaceutical & Biotechnology Companies	Contract Research Organization
Application Scope	Cancer, Immunological Disease, Infectious Disease, Others	Cancer	Cancer
Animal Type Scope	Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Others	Mice	Mice

Competitive Landscape and Market Positioning

Key companies in the animal model market:

1. Charles River Laboratories International Inc. (United States)

2. The Jackson Laboratory (United States)

3. Taconic Biosciences Inc. (United States)

4. genOway S.A. (France)

5. Janvier Labs (France)

6. Crown Bioscience Inc. (United States)

7. Inotiv Inc. (United States)

8. Biocytogen Pharmaceuticals (Beijing) Co. Ltd. (China)

9. Envigo RMS LLC (United States)

10. Harbour BioMed Ltd. (China)

Advancements in precision research techniques are significantly shaping the animal model market, with organizations emphasizing the development of highly specialized disease models for therapeutic research. Increased investment in genetic engineering technologies and personalized medicine applications is driving innovation across preclinical testing environments. Additionally, expanded research collaborations and laboratory infrastructure upgrades are improving the availability and diversity of advanced animal model solutions.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	Medium	Few key players (e.g., Charles River, Jackson Lab) are dominant, but smaller firms also compete.
M&A Activity / Consolidation Trend	Active	Ongoing acquisitions to expand genetic model portfolios, e.g., Taconic Biosciences in 2024.
Degree of Product Differentiation	High	Specialized models (e.g., transgenic mice) tailored for specific research needs.
Competitive Advantage Sustainability	Durable	Proprietary genetic models and expertise create barriers to entry.
Innovation Intensity	High	Continuous R&D in CRISPR and genetic engineering drives new model development.
Customer Loyalty / Stickiness	Strong	Long-term contracts with research institutes due to specialized offerings.
Vertical Integration Level	Medium	Partial integration in breeding and distribution; some outsourcing for logistics.

Industry Development/News

Company Name	Date	Key Development
Taconic Biosciences	Aug-25	Taconic Biosciences and Cyagen established a strategic partnership across North America and Europe to consolidate access to a library of over 16,000 genetically engineered mouse and rat models. This collaboration streamlines the supply chain for preclinical research, enabling faster procurement of standardized biological models to accelerate drug discovery and development timelines.
Atelerix	Dec-25	Atelerix entered a collaborative agreement with Cherry Biotech to integrate its hydrogel preservation technology with advanced organoid research workflows. By facilitating the storage and transport of complex biological models, this partnership improves the efficiency of preclinical handling and supports the scaling of alternative, non-animal-based model systems in biomedical research.
China National Macaque Biobank	Oct-25	The establishment of China's first national macaque biobank, following the analysis of nearly 1,000 subjects, significantly enhances the availability of standardized non-human primate (NHP) resources. This infrastructure project improves the precision and reliability of disease modeling for complex biomedical applications, representing a major regional expansion in high-tier preclinical research capabilities.
Applied StemCell	Feb-25	Applied StemCell reported technical advancements in its proprietary TARGATT gene-editing platform, broadening its utility for generating complex, genetically engineered animal models. These upgrades enhance the platform’s commercial viability for contract research and internal product development, providing researchers with more precise tools to study gene function and disease pathology in preclinical environments.
Recombinetics	Nov-24	Recombinetics, a developer of gene-edited livestock models, filed for bankruptcy protection amid significant financial liabilities. This exit marks a contraction in the specialized market for agricultural-based animal models, illustrating the high capital intensity and commercial challenges inherent in scaling advanced genetic engineering technologies for commercial and research-driven applications.
Parallel Bio	Aug-24	Parallel Bio commercialized a human immune system platform designed as a direct substitute for traditional in vivo animal testing. By enabling the evaluation of immunotherapies within human-based model systems, the company provides a technological alternative that competes with traditional animal-model workflows, reflecting shifting industry demand toward human-centric preclinical diagnostic tools.
Cemib	Jan-24	Cemib inaugurated a new production facility featuring upgraded technological infrastructure for the generation of genetically modified laboratory animals. This expansion increases regional production capacity and operational bandwidth for the provision of sophisticated animal models, supporting the growing demand for specialized research tools required in advanced pharmaceutical and biotechnological product development.
Taconic Biosciences	Nov-22	Avista Capital Partners completed the acquisition of Taconic Biosciences, integrating the firm into its healthcare portfolio. The transaction provided the necessary capital and strategic resources to accelerate the expansion of Taconic’s genetically engineered rodent model (GEM) portfolio and associated preclinical services, reinforcing its competitive position in the global laboratory animal market.
Taconic Biosciences	Aug-25	Taconic Biosciences and Cyagen established a strategic partnership across North America and Europe to consolidate access to a library of over 16,000 genetically engineered mouse and rat models. This collaboration streamlines the supply chain for preclinical research, enabling faster procurement of standardized biological models to accelerate drug discovery and development timelines.
Atelerix	Dec-25	Atelerix entered a collaborative agreement with Cherry Biotech to integrate its hydrogel preservation technology with advanced organoid research workflows. By facilitating the storage and transport of complex biological models, this partnership improves the efficiency of preclinical handling and supports the scaling of alternative, non-animal-based model systems in biomedical research.
China National Macaque Biobank	Oct-25	The establishment of China's first national macaque biobank, following the analysis of nearly 1,000 subjects, significantly enhances the availability of standardized non-human primate (NHP) resources. This infrastructure project improves the precision and reliability of disease modeling for complex biomedical applications, representing a major regional expansion in high-tier preclinical research capabilities.
Applied StemCell	Feb-25	Applied StemCell reported technical advancements in its proprietary TARGATT gene-editing platform, broadening its utility for generating complex, genetically engineered animal models. These upgrades enhance the platform’s commercial viability for contract research and internal product development, providing researchers with more precise tools to study gene function and disease pathology in preclinical environments.
Recombinetics	Nov-24	Recombinetics, a developer of gene-edited livestock models, filed for bankruptcy protection amid significant financial liabilities. This exit marks a contraction in the specialized market for agricultural-based animal models, illustrating the high capital intensity and commercial challenges inherent in scaling advanced genetic engineering technologies for commercial and research-driven applications.
Parallel Bio	Aug-24	Parallel Bio commercialized a human immune system platform designed as a direct substitute for traditional in vivo animal testing. By enabling the evaluation of immunotherapies within human-based model systems, the company provides a technological alternative that competes with traditional animal-model workflows, reflecting shifting industry demand toward human-centric preclinical diagnostic tools.
Cemib	Jan-24	Cemib inaugurated a new production facility featuring upgraded technological infrastructure for the generation of genetically modified laboratory animals. This expansion increases regional production capacity and operational bandwidth for the provision of sophisticated animal models, supporting the growing demand for specialized research tools required in advanced pharmaceutical and biotechnological product development.
Taconic Biosciences	Nov-22	Avista Capital Partners completed the acquisition of Taconic Biosciences, integrating the firm into its healthcare portfolio. The transaction provided the necessary capital and strategic resources to accelerate the expansion of Taconic’s genetically engineered rodent model (GEM) portfolio and associated preclinical services, reinforcing its competitive position in the global laboratory animal market.